Dasatinib-Induced Colitis: Risk of misdiagnosis of inflammatory bowel disease. A case report and review of the literature

Graziana Arborea*, Anna Maria Valentini, Stefania Marangi, Nicoletta Labarile LT and Maria Teresa Savino

Dasatinib is a potent tyrosine kinase inhibitor, in disease states associated with BCR/ABL 1, approved in 2006 for chronic myeloid leukemia treatment. This agent has been shown to exhibit broad off-target kinase inhibition and immunomodulating properties. These effects may be responsible for common adverse reactions (> 15%) which include immunosuppression, cytopenias, pleural effusion and other fluid retention, diarrhea, and other gastrointestinal side effects.

Although gastrointestinal bleeding is a well-documented side effect, the presentation of colitis is an uncommon occurrence.

In most cases, it is hemorrhagic colitis, nonspecific colitis, or CMV-related colitis.

We report a 34-year-old male patient affected by CML in treatment with Dasatinib for approximately 1 year, who reported chronic diarrhea which progressed to suspected Dasatinib-induced colitis whose clinical, endoscopic, and histological findings overlapped those of Inflammatory Bowel Disease.

Keywords:

Published on: May 24, 2023 Pages: 6-11

Full Text PDF Full Text HTML DOI: 10.17352/ijpsdr.000046
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat